logo-loader
viewN4 Pharma PLC

N4 Pharma's Nuvec platform 'on a clear path' towards clinical trials

N4 Pharma PLC (LON:N4P) CEO Nigel Theobald speaks to Proactive London's Andrew Scott following the release of the firm's interim results to June 2019.

He says it's been an incredibly active period for them where, among a number of developments, they've confirmed that Nuvec® works for both DNA and mRNA delivery.

Quick facts: N4 Pharma PLC

Price: 3.25 GBX

AIM:N4P
Market: AIM
Market Cap: £3.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Bacanora Lithium CEO hails completion of strategic...

Bacanora Lithium PLC's (LON:BCN) Peter Secker speaks to Proactive London's Andrew Scott following approval from the relevant Chinese authorities for Gangfeng Lithium Co Ltd to complete its strategic investment in the company. Bacanora is now in receipt of £21.9mln of funds from Ganfeng, and...

8 hours, 57 minutes ago

2 min read